Literature DB >> 19117959

Optimal dosing of intravenous unfractionated heparin bolus in transient ischemic attack or stroke.

Kyusik Kang1, Hee-Kwon Park, Byung-Woo Yoon.   

Abstract

Early initiation of heparin therapy for treatment of stroke is not only associated with an improved outcome, but also with the risk of hemorrhagic transformation. We compared the efficacy of three unfractionated heparin bolus regimens (0 U/kg, 30 U/kg, or 80 U/kg) in achieving a therapeutic activated partial thromboplastin time over the first 6-hour period in a cohort of 54 patients admitted with transient ischemic attack or stroke. Patients treated with the low bolus dose (30 U/kg) were more often within the therapeutic range for activated partial thromboplastin time at two hours after the initial bolus than patients treated with the other regimens. The percentage of therapeutic activated partial thromboplastin time results within the first six hours of treatment was greater in the group treated with the low bolus dose. Using the low bolus dose may reduce complication rates and improve clinical outcomes in the future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19117959     DOI: 10.1177/1076029608329579

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

Review 1.  Anticoagulants for acute ischaemic stroke.

Authors:  Xia Wang; Menglu Ouyang; Jie Yang; Lili Song; Min Yang; Craig S Anderson
Journal:  Cochrane Database Syst Rev       Date:  2021-10-22

Review 2.  Anticoagulants for acute ischaemic stroke.

Authors:  Peter A G Sandercock; Carl Counsell; Edward J Kane
Journal:  Cochrane Database Syst Rev       Date:  2015-03-12

3.  Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials.

Authors:  William N Whiteley; Harold P Adams; Philip M W Bath; Eivind Berge; Per Morten Sandset; Martin Dennis; Gordon D Murray; Ka-Sing Lawrence Wong; Peter A G Sandercock
Journal:  Lancet Neurol       Date:  2013-05-02       Impact factor: 44.182

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.